ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ACHV / news
MYGN (47) QDEL (21) NNNN (35) TKNO (42) ⌘ Pro Terminal →

Why ACHV Stock dropped -3.22% Today — RQD Quant Desk Flash

$6.61 -3.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.56

Achieve Life Sciences Inc. (ACHV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $702.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACHV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACHV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Achieve Life Sciences Inc. (NASDAQ: ACHV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.61 (-3.22% 1D, market cap $702.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ACHV ranks #484 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACHV compare to MYGN and QDEL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ACHV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M) and QDEL (QuidelOrtho Corporation) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $908.6M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACHV?
▼

Per ACHV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000949858), Achieve Life Sciences Inc. generated $17.6M in revenue (+8.2% YoY), -$54.6M in net income, and -$49.5M in free cash flow against $41.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.56 (-0.77%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (10)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$9 Bull$6 Base$5 Bear
📬 FREE ACHV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACHV)Realized 20D OHLCV Swing Band: ±11.8%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ACHV SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$7.00-7% Next Q
Q2 (-2Q)
44
Grade D$6.51+6.5% Next Q
Q3 (-1Q)
42
Grade D$6.93-4.6% Next Q
Current
39
Grade D-$6.61-7.6% Hist 90D α
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACHV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACHV currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.41) and Max Pain ($6.94) forces dealer call-delta covering toward $9.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACHV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACHV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ACHV Stock dropped -3.22% Today — RQD Quant Desk Flash

Achieve Life Sciences Inc. (ACHV) dropped -3.22% to $6.61, trading at 66% of its 52-week range ($2.62 – $8.64). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 66% of its 52-week range ($2.62 – $8.64) with RSI-14 at 46.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±11.8% around $6.61 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ACHV Headlines & Catalysts
RISK WATCHYahoo • 19d ago
Lisata adds biopharma finance veteran Jeffrey Farrow to board

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHV)

  • ✓Walkthrough of ACHV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ACHV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.57%🛡️ HOLDING TREND SUPPORT
2026-11-03O $7.19H $7.19L $6.61C $6.61VOL 1.38M
RES: $10.53SUP: $6.31SMA50: $7.41SMA200: $5.65
$8.97$7.60$6.24$4.87$3.51RES $10.53SUP $6.31$6.612026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACHV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACHV Butterfly Map → + Track ACHV →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACHV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACHV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACHV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHV)

Health Care Rank #484 of 1015 ⚔️ MYGN vs ACHV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACHV vs. MYGN, QDEL, NNNN, TKNO)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Achieve Life Sciences Inc. (ACHV) ranks #484 by composite RQD confidence (39/100, grade D-) and #394 by equity capitalization ($702.8M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACHV at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACHV ACTIVE
Achieve Life Sciences Inc.
D- 39/100 — — -35.0% -3.22% $702.8M Benchmark Subject
MYGN
Myriad Genetics Inc.
D 47/100 — 69.9% -35.0% -7.87% $607.4M /mygn-vs-achv →
QDEL
QuidelOrtho Corporation
E 21/100 — — -35.0% +5.89% $908.6M /qdel-vs-achv →
NNNN
Anbio Biotechnology (Class A)
D- 35/100 83.6x 87.2% 17.0% +4.46% $483.5M /nnnn-vs-achv →
TKNO
Alpha Teknova Inc.
D- 42/100 — 33.2% -21.3% -4.75% $454.1M /tkno-vs-achv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000949858 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported GAAP revenue of $17.6M (+8.2% vs. FY2024 revenue of $16.2M , and -86.9% cumulative change since FY2023) , GAAP net income of -$54.6M, operating cash flow of -$49.5M, and free cash flow of -$49.5M (-66.2% YoY). On the balance sheet, ACHV closed FY2025 with $41.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $17.6M -$54.6M -$49.5M -$49.5M $41.8M —
FY2024 (FY) 2024-12-31 $16.2M -$39.8M -$29.8M -$29.8M $38.6M —
FY2023 (FY) 2023-12-31 $134.2M -$29.8M -$24.5M -$24.5M — —

3. ACHV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACHV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Achieve Life Sciences Inc. (NASDAQ: ACHV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.61 (-3.22% 1D, market cap $702.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ACHV ranks #484 in composite RQD confidence.

How does ACHV compare to MYGN and QDEL in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ACHV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M) and QDEL (QuidelOrtho Corporation) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $908.6M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACHV?

Per ACHV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000949858), Achieve Life Sciences Inc. generated $17.6M in revenue (+8.2% YoY), -$54.6M in net income, and -$49.5M in free cash flow against $41.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACHV trading relative to its 50-day, 200-day, and 52-week technical levels?

ACHV last traded at $6.61 (-3.22% on volume of 1,531,856 shares), positioning the stock -10.80% below its 50-day simple moving average ($7.41) and +16.99% above its 200-day simple moving average ($5.65). Across its 52-week range of $2.62 to $8.64, ACHV sits at the 66.3% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($5.83 to $7.39).

Direct Sub-Reports: ACHV RQD Cockpit ACHV 12M Forecast ACHV Earnings & Move ACHV Dividends & DRIP ACHV Insiders & 13F ACHV Whale Options ACHV Profit Sankey ACHV News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ACHV — Achieve Life Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Achieve Life Sciences Inc. (ACHV) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.61 (-3.22% 1D, market capitalization $702.8M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.69%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Achieve Life Sciences Inc. (ACHV) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Achieve Life Sciences Inc. (ACHV) reported $17.6M in annual revenue (up from $16.2M in FY2024, +8.2% YoY) and -$54.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($134.2M revenue, -$29.8M net income) through FY2025, ACHV scaled operating cash flow to -$49.5M and free cash flow to -$49.5M, backed by $41.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.69% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $2.62 – $8.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ACHV carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ACHV sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $17.6M and free cash flow of -$49.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ACHV's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACHV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Achieve Life Sciences Inc. (ACHV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACHV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACHV Bull vs. Bear Conversation Board — What's Your Call at $6.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACHV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ACHV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $8.40 (+23.0%)
📌 Pinned Debate

Whale/13F flow scores 11 of 20 and the stock rose 4.96% to $7.19, near the upper end of its $2.62–$8.64 52-week range.

The street is overcomplicating Achieve Life Sciences Inc. (ACHV). Whale/13F flow scores 11 of 20 and the stock rose 4.96% to $7.19, near the upper end of its $2.62–$8.64 52-week range.. With an RQD score of 39/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $7.38.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 10/20 institutional whale-flow stock at $6.83 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $5.40 (-20.9%)
Spot @ $6.83

ROIC of -35%, FCF of -$49.5M, and a Piotroski F-Score of 2/9 indicate a weak cash engine and balance-sheet profile.

ROIC of -35%, FCF of -$49.5M, and a Piotroski F-Score of 2/9 indicate a weak cash engine and balance-sheet profile.. Look at the math on ACHV: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $6.01 before getting long.

LIVE TAPE